Trial Profile
A Randomized, Placebo-controlled, Double-blind, Multicentre, Multiple Dose, Cohort Study With Escalating Doses to Evaluate the Safety and Efficacy of the Humanized Monoclonal Antibody BT061 Administered to Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Tregalizumab (Primary) ; Tregalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 24 Mar 2012 This trial is recruiting in Hungary as reported by European Clinical Trials Database record.
- 12 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual patients number is 49 as reported by ClinicalTrials.gov.